Chronic myeloproliferative diseases: Polycythemia, thrombocythemia, myelofibrosis - Preface
2006-01-01 Lazzarino, Mario; Cazzola, Mario; Passamonti, Francesco
Molecular characterization of Philadelphia-negative myeloproliferative neoplasms
2010-01-01 Brisci, Angela; Pietra, Daniela; Foglieni, Barbara; Boggi, Sabrina; Rumi, Elisa; Passamonti, Francesco; Ferrari, Maurizio; Cremonesi, Laura
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.
2010-01-01 Paulli, Marco; Arcaini, L; Lucioni, M; Boveri, E; Capello, D; Passamonti, Francesco; Merli, M; Rattotti, S; Rossi, D; Riboni, R; Berti, E; Magrini, U; Bruno, R; Gaidano, G; Lazzarino, M.
SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS ARE INDOLENT DISORDERS AT HIGH HEPATITIS C VIRUS SEROPREVALENCE WITH DISTINCT PRESENTING FEATURES BUT SIMILAR MORPHOLOGIC AND PHENOTYPIC PROFILES
2004-01-01 Arcaini, L; Paulli, Marco; Boveri, E; Vallisa, D; Bernuzzi, P; Orlandi, E; Incardona, P; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Schena, C; Pascutto, C; Cavanna, L; Magrini, U; Lazzarino, M.
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY.
1999-01-01 Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, Francesco; CARLO STELLA, C.; Santoro, A.; Siena, S.
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA
2002-01-01 Bernasconi, P.; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C.
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires
2009-01-01 Arcaini, L; Zibellini, S; Passamonti, Francesco; Rattotti, S; Lucioni, M; Invernizzi, R; Merli, M; Rizzi, S; Boveri, E; Rumi, E; Astori, C; Picone, C; Varettoni, M; Pascutto, C; Paulli, Marco; Lazzarino, M.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
2009-01-01 Cervantes, F; Dupriez, B; Pereira, A; Passamonti, Francesco; Reilly, Jt; Morra, E; Vannucchi, Am; Mesa, Ra; Demory, Jl; Barosi, G; Rumi, E; Tefferi, A.
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations
2008-01-01 Boveri, E; Passamonti, Francesco; Rumi, E; Pietra, D; Elena, C; Arcaini, L; Pascutto, C; Castello, A; Cazzola, M; Magrini, U; Lazzarino, M.
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
2005-01-01 Malcovati, L; Della Porta, Mg; Pascutto, C; Invernizzi, R; Boni, M; Travaglino, E; Passamonti, Francesco; Arcaini, L; Maffioli, M; Bernasconi, P; Lazzarino, M; Cazzola, M.
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
2008-01-01 Arcaini, L; Montanari, F; Alessandrino, Ep; Tucci, A; Brusamolino, E; Gargantini, L; Cairoli, R; Bernasconi, P; Passamonti, Francesco; Bonfichi, M; Zoli, V; Bottelli, C; Calatroni, S; Troletti, D; Merli, M; Pascutto, C; Majolino, I; Rossi, G; Morra, E; Lazzarino, M.
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
2008-01-01 Passamonti, Francesco; Rumi, E; Arcaini, L; Boveri, E; Elena, C; Pietra, C; Boggi, S; Astori, C; Bernasconi, P; Varettoni, M; Brusamolino, E; Pascutto, C; Lazzarino, M.
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders
2006-01-01 Rumi, E; Passamonti, Francesco; Pietra, D; Della Porta, Mg; Arcaini, L; Boggi, S; Elena, C; Boveri, E; Pascutto, C; Lazzarino, M; Cazzola, M.
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia.
2009-01-01 Passamonti, Francesco; Rumi, E; Pascutto, C; Cazzola, M; Lazzarino, M.
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
2009-01-01 Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, Hc; Kiladjian, Jj; Lengfelder, E; Mcmullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T.
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients
2009-01-01 Siragusa, S; Passamonti, Francesco; Cervantes, F; Tefferi, A.
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug
2004-01-01 Passamonti, Francesco; Cazzola, M.
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
2009-01-01 Malcovati, L; Della Porta, Mg; Pietra, D; Boveri, E; Pellagatti, A; Gallì, A; Travaglino, E; Brisci, A; Rumi, E; Passamonti, Francesco; Invernizzi, R; Cremonesi, L; Boultwood, J; Wainscoat, Js; Hellström Lindberg, E; Cazzola, M.
New and old prognostic factors in polycythemia vera
2009-01-01 Passamonti, Francesco
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
2009-01-01 Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, H; Kiladijan, Jj; Lengfelder, E; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Chronic myeloproliferative diseases: Polycythemia, thrombocythemia, myelofibrosis - Preface | 1-gen-2006 | Lazzarino, Mario; Cazzola, Mario; Passamonti, Francesco | |
| Molecular characterization of Philadelphia-negative myeloproliferative neoplasms | 1-gen-2010 | Brisci, Angela; Pietra, Daniela; Foglieni, Barbara; Boggi, Sabrina; Rumi, Elisa; Passamonti, Francesco; Ferrari, Maurizio; Cremonesi, Laura | |
| Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. | 1-gen-2010 | Paulli, Marco; Arcaini, L; Lucioni, M; Boveri, E; Capello, D; Passamonti, Francesco; Merli, M; Rattotti, S; Rossi, D; Riboni, R; Berti, E; Magrini, U; Bruno, R; Gaidano, G; Lazzarino, M. | |
| SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS ARE INDOLENT DISORDERS AT HIGH HEPATITIS C VIRUS SEROPREVALENCE WITH DISTINCT PRESENTING FEATURES BUT SIMILAR MORPHOLOGIC AND PHENOTYPIC PROFILES | 1-gen-2004 | Arcaini, L; Paulli, Marco; Boveri, E; Vallisa, D; Bernuzzi, P; Orlandi, E; Incardona, P; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Schena, C; Pascutto, C; Cavanna, L; Magrini, U; Lazzarino, M. | |
| EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. | 1-gen-1999 | Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, Francesco; CARLO STELLA, C.; Santoro, A.; Siena, S. | |
| ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA | 1-gen-2002 | Bernasconi, P.; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C. | |
| Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires | 1-gen-2009 | Arcaini, L; Zibellini, S; Passamonti, Francesco; Rattotti, S; Lucioni, M; Invernizzi, R; Merli, M; Rizzi, S; Boveri, E; Rumi, E; Astori, C; Picone, C; Varettoni, M; Pascutto, C; Paulli, Marco; Lazzarino, M. | |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | 1-gen-2009 | Cervantes, F; Dupriez, B; Pereira, A; Passamonti, Francesco; Reilly, Jt; Morra, E; Vannucchi, Am; Mesa, Ra; Demory, Jl; Barosi, G; Rumi, E; Tefferi, A. | |
| Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations | 1-gen-2008 | Boveri, E; Passamonti, Francesco; Rumi, E; Pietra, D; Elena, C; Arcaini, L; Pascutto, C; Castello, A; Cazzola, M; Magrini, U; Lazzarino, M. | |
| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making | 1-gen-2005 | Malcovati, L; Della Porta, Mg; Pascutto, C; Invernizzi, R; Boni, M; Travaglino, E; Passamonti, Francesco; Arcaini, L; Maffioli, M; Bernasconi, P; Lazzarino, M; Cazzola, M. | |
| Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma | 1-gen-2008 | Arcaini, L; Montanari, F; Alessandrino, Ep; Tucci, A; Brusamolino, E; Gargantini, L; Cairoli, R; Bernasconi, P; Passamonti, Francesco; Bonfichi, M; Zoli, V; Bottelli, C; Calatroni, S; Troletti, D; Merli, M; Pascutto, C; Majolino, I; Rossi, G; Morra, E; Lazzarino, M. | |
| Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients | 1-gen-2008 | Passamonti, Francesco; Rumi, E; Arcaini, L; Boveri, E; Elena, C; Pietra, C; Boggi, S; Astori, C; Bernasconi, P; Varettoni, M; Brusamolino, E; Pascutto, C; Lazzarino, M. | |
| JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders | 1-gen-2006 | Rumi, E; Passamonti, Francesco; Pietra, D; Della Porta, Mg; Arcaini, L; Boggi, S; Elena, C; Boveri, E; Pascutto, C; Lazzarino, M; Cazzola, M. | |
| Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. | 1-gen-2009 | Passamonti, Francesco; Rumi, E; Pascutto, C; Cazzola, M; Lazzarino, M. | |
| Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | 1-gen-2009 | Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, Hc; Kiladjian, Jj; Lengfelder, E; Mcmullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T. | |
| Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients | 1-gen-2009 | Siragusa, S; Passamonti, Francesco; Cervantes, F; Tefferi, A. | |
| Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug | 1-gen-2004 | Passamonti, Francesco; Cazzola, M. | |
| Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. | 1-gen-2009 | Malcovati, L; Della Porta, Mg; Pietra, D; Boveri, E; Pellagatti, A; Gallì, A; Travaglino, E; Brisci, A; Rumi, E; Passamonti, Francesco; Invernizzi, R; Cremonesi, L; Boultwood, J; Wainscoat, Js; Hellström Lindberg, E; Cazzola, M. | |
| New and old prognostic factors in polycythemia vera | 1-gen-2009 | Passamonti, Francesco | |
| A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | 1-gen-2009 | Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, H; Kiladijan, Jj; Lengfelder, E; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Articoli su Riviste35072
Data di pubblicazione
- In corso di stampa25
- 2020 - 202710392
- 2010 - 201911782
- 2000 - 20097850
- 1990 - 19993601
- 1980 - 19891162
- 1970 - 1979252
- 1967 - 19698
Editore
- Edizioni Luigi Pozzi Srl:via Pana...51
- Japadre Editore, L'Aquila36
- WILEY34
- Elsevier BV:PO Box 211, 1000 AE A...31
- ELSEVIER SCIENCE BV29
- Franco Angeli Riviste SRL:viale M...28
- Springer Verlag Germany:Tiergarte...28
- -Roma: [s.n.]. -Artegierre-Esseze...26
- Elsevier B.V.23
- Royal Society of Chemistry:Thomas...21
Rivista
- PHYSICAL REVIEW LETTERS216
- LA RADIOLOGIA MEDICA180
- NUCLEAR INSTRUMENTS & METHODS IN ...176
- ASTRONOMY & ASTROPHYSICS168
- MONTHLY NOTICES OF THE ROYAL ASTR...165
- PHYSICS LETTERS. SECTION B154
- PLOS ONE152
- SCIENTIFIC REPORTS151
- THROMBOSIS AND HAEMOSTASIS145
- IL PROTAGORA140
Serie
- PROCEEDINGS OF INTERNATIONAL MATH...1
Keyword
- Humans1605
- Female801
- Male679
- Middle Aged514
- COVID-19506
- Aged475
- Adult453
- Italy337
- SARS-CoV-2310
- Treatment Outcome237
Lingua
- eng18787
- ita2905
- fre60
- spa55
- ger35
- por14
- bul9
- rus8
- gre6
- chi3
Accesso al fulltext
- no fulltext24541
- reserved5244
- open5084
- restricted107
- partially open93
- mixed2
- embargoed1